Efficacy and Safety of Liraglutide vs. Placebo as Add-On to Existing Diabetes Medication in Subjects with Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL)

Efficacy And Safety ◽

Diabetes Medication

OP60 EFFICACY AND SAFETY OF LIRAGLUTIDE VERSUS PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT (LIRA-RENAL): A RANDOMISED TRIAL

Diabetes Research and Clinical Practice ◽

10.1016/s0168-8227(14)70266-9 ◽

2014 ◽

Vol 106 ◽

pp. S31 ◽

Cited By ~ 1

Author(s):

C. Mathieu ◽

G. Umpierrez ◽

S. Atkin ◽

S. Bain ◽

P. Rossing ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Randomised Trial ◽

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment

Diabetes Therapy ◽

10.1007/s13300-016-0184-9 ◽

2016 ◽

Vol 7 (3) ◽

pp. 527-535 ◽

Cited By ~ 1

Author(s):

Shira Perl ◽

William Cook ◽

Cheryl Wei ◽

Nayyar Iqbal ◽

Boaz Hirshberg

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

136-LB: Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Moderate Renal Impairment

Diabetes ◽

10.2337/db20-136-lb ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 136-LB

Author(s):

DAVID CHERNEY ◽

ELE FERRANNINI ◽

GUILLERMO E. UMPIERREZ ◽

ANNE L. PETERS ◽

JULIO ROSENSTOCK ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial

Diabetes Care ◽

10.2337/dc14-2883 ◽

2015 ◽

pp. dc142883 ◽

Cited By ~ 14

Author(s):

Melanie J. Davies ◽

Stephen C. Bain ◽

Stephen L. Atkin ◽

Peter Rossing ◽

David Scott ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Renal Impairment ◽

Randomized Clinical Trial ◽

Efficacy And Safety ◽

Glucose Lowering ◽

Lowering Therapy ◽

Glucose Lowering Therapy

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(19)30192-5 ◽

2019 ◽

Vol 7 (7) ◽

pp. 515-527 ◽

Cited By ~ 46

Author(s):

Ofri Mosenzon ◽

Thalia Marie Blicher ◽

Signe Rosenlund ◽

Jan W Eriksson ◽

Simon Heller ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

Diabetes Obesity and Metabolism ◽

10.1111/dom.13413 ◽

2018 ◽

Vol 20 (11) ◽

pp. 2532-2540 ◽

Cited By ~ 45

Author(s):

Paola Fioretto ◽

Stefano Del Prato ◽

John B. Buse ◽

Ronald Goldenberg ◽

Francesco Giorgino ◽

...

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Renal Impairment ◽

Chronic Kidney Disease Stage ◽

Disease Stage ◽

1004-P: Oral Semaglutide vs. Placebo in Patients with Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5

Diabetes ◽

10.2337/db19-1004-p ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 1004-P ◽

Cited By ~ 1

Author(s):

OFRI MOSENZON ◽

SIGNE ROSENLUND ◽

JAN W. ERIKSSON ◽

SIMON R. HELLER ◽

RICHARD E. PRATLEY ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Moderate Renal Impairment

Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin

Therapeutics and Clinical Risk Management ◽

10.2147/tcrm.s67076 ◽

2015 ◽

pp. 799 ◽

Cited By ~ 6

Author(s):

Baptist Gallwitz

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Moderate Renal Impairment

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

Diabetes Care ◽

10.2337/dc12-0706 ◽

2012 ◽

Vol 36 (2) ◽

pp. 237-244 ◽

Cited By ~ 120

Author(s):

J. B. McGill ◽

L. Sloan ◽

J. Newman ◽

S. Patel ◽

C. Sauce ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Severe Renal Impairment ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy

Glycemic Control and Hypoglycemia Benefits with Insulin Glargine 300 U/mL (Gla-300) Extend to People with Type 2 Diabetes and Mild-to-Moderate Renal Impairment

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2016.08.135 ◽

2016 ◽

Vol 40 (5) ◽

pp. S47

Author(s):

Peter A. Senior ◽

Javier Escalada ◽

Serge Halimi ◽

Mireille Bonnemaire ◽

Anna M.G. Cali ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Renal Impairment ◽

Insulin Glargine ◽

Moderate Renal Impairment